Free Trial

BioVie (BIVI) Competitors

BioVie logo
$7.85 -1.75 (-18.23%)
As of 03:39 PM Eastern

BIVI vs. ZURA, ONCY, QNCX, PYXS, BMEA, INCR, ABOS, IMUX, IKNA, and MNOV

Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Zura Bio (ZURA), Oncolytics Biotech (ONCY), Quince Therapeutics (QNCX), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Ikena Oncology (IKNA), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry.

BioVie vs. Its Competitors

Zura Bio (NASDAQ:ZURA) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, BioVie had 1 more articles in the media than Zura Bio. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.71 beat BioVie's score of 0.30 indicating that Zura Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zura Bio
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
BioVie
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Zura Bio currently has a consensus price target of $14.33, indicating a potential upside of 1,179.76%. Given Zura Bio's higher probable upside, analysts clearly believe Zura Bio is more favorable than BioVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zura Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
BioVie
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

Zura Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zura BioN/AN/A-$45.39M-$0.70-1.60
BioVieN/AN/A-$32.12M-$7.91-0.99

Zura Bio has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 22.1% of Zura Bio shares are owned by company insiders. Comparatively, 2.4% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zura Bio's return on equity of -42.84% beat BioVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Zura BioN/A -42.84% -35.22%
BioVie N/A -100.88%-78.49%

Summary

Zura Bio beats BioVie on 8 of the 13 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIVI vs. The Competition

MetricBioVieMED IndustryMedical SectorNASDAQ Exchange
Market Cap$145.77M$2.37B$5.45B$8.92B
Dividend YieldN/A1.78%5.22%4.00%
P/E Ratio-0.998.8927.2720.07
Price / SalesN/A663.55428.46118.22
Price / CashN/A21.7726.2128.59
Price / Book3.094.507.925.58
Net Income-$32.12M$31.26M$3.17B$248.65M
7 Day Performance748.64%5.30%4.33%7.15%
1 Month Performance626.84%5.63%2.61%8.13%
1 Year Performance1,819.29%8.72%34.78%21.59%

BioVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIVI
BioVie
0.3704 of 5 stars
$7.85
-18.2%
N/A+135.2%$145.77MN/A-0.9910
ZURA
Zura Bio
3.5019 of 5 stars
$1.05
flat
$14.33
+1,265.1%
-67.5%$71.79MN/A-1.503Positive News
Gap Up
ONCY
Oncolytics Biotech
1.6659 of 5 stars
$0.77
+3.0%
$4.33
+460.6%
-12.5%$70.77MN/A-2.6730Gap Down
QNCX
Quince Therapeutics
2.8921 of 5 stars
$1.65
+6.5%
$8.00
+384.8%
+120.1%$70.48MN/A-1.1960
PYXS
Pyxis Oncology
1.2151 of 5 stars
$1.10
flat
$9.00
+718.2%
-61.6%$68.14M$16.15M-0.6960Positive News
BMEA
Biomea Fusion
2.5595 of 5 stars
$1.80
-0.6%
$21.40
+1,088.9%
-60.9%$68.01MN/A-0.5150
INCR
InterCure
N/A$1.47
-1.3%
N/A-35.4%$67.90M$66.28M0.00350High Trading Volume
ABOS
Acumen Pharmaceuticals
1.2512 of 5 stars
$1.16
+3.6%
$6.33
+446.0%
-49.6%$67.84MN/A-0.6020
IMUX
Immunic
2.9419 of 5 stars
$0.70
-0.4%
$11.60
+1,563.1%
-32.5%$67.07MN/A-0.5770Positive News
IKNA
Ikena Oncology
2.3757 of 5 stars
$1.34
-1.5%
$3.00
+123.9%
-19.9%$65.63M$9.16M-1.5670Positive News
MNOV
MediciNova
1.8421 of 5 stars
$1.31
-1.5%
$7.00
+434.4%
-10.6%$65.23M$1M-5.7010Gap Down

Related Companies and Tools


This page (NASDAQ:BIVI) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners